ELDN vs. DAWN, GHRS, SION, STOK, CDXC, XNCR, KALV, EOLS, SANA, and UPB
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Sionna Therapeutics (SION), Stoke Therapeutics (STOK), ChromaDex (CDXC), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Evolus (EOLS), Sana Biotechnology (SANA), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.
Eledon Pharmaceuticals vs. Its Competitors
Eledon Pharmaceuticals (NASDAQ:ELDN) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.
56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Eledon Pharmaceuticals has higher earnings, but lower revenue than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eledon Pharmaceuticals presently has a consensus target price of $9.00, suggesting a potential upside of 199.50%. Day One Biopharmaceuticals has a consensus target price of $30.57, suggesting a potential upside of 349.58%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Day One Biopharmaceuticals is more favorable than Eledon Pharmaceuticals.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -42.66%. Day One Biopharmaceuticals' return on equity of -14.98% beat Eledon Pharmaceuticals' return on equity.
In the previous week, Eledon Pharmaceuticals and Eledon Pharmaceuticals both had 1 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 0.00 equaled Day One Biopharmaceuticals'average media sentiment score.
Eledon Pharmaceuticals has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.27, meaning that its share price is 227% less volatile than the S&P 500.
Summary
Day One Biopharmaceuticals beats Eledon Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ELDN) was last updated on 7/5/2025 by MarketBeat.com Staff
Free ELDN Stock Alerts